Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ FAM3C Monoclonal Antibody (438618)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA524162
Description
In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) FAM3A, rhFAM3B, recombinant mouse (rm) FAM3C, or rmFAM3D is observed. Reconstitute at 0.5 mg/mL in sterile PBS.
FAM3C is a 227 amino acid secretory protein that belongs to a novel cytokine-like family with sequence similarity to FAM3 family. FAM3C is a signaling cytokine with a GG domain, hydrophobic leader sequence and an N-terminal signal peptide. FAM3C has a cytokine activity and shows a change in expression in pancreatic cancer-derived cells. It is ubiquitously expressed in most of the tissues. Reports suggest that FAM3C plays an important role in inner ear development and may thus be involved in cell differentiation and proliferation during inner ear embryogenesis.
Specifications
FAM3C | |
Monoclonal | |
0.5 mg/mL | |
PBS with 5% trehalose and No Preservative | |
Q92520 | |
FAM3C | |
Mouse myeloma cell line NS0-derived recombinant human FAM3C Gln25-Asp227. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG2b |
Western Blot, Immunocytochemistry | |
438618 | |
Unconjugated | |
FAM3C | |
D6Wsu176e; FAM3 metabolism regulating signaling molecule C; Fam3c; fam3c protein; FAM3C-like protein; family with sequence similarity 3 member C; family with sequence similarity 3, member C; GS3786; Ilei; Interleukin-like EMT inducer; interleukin-like epithelial-mesenchymal transition inducer; predicted osteoblast protein; protein FAM3C; si:dkey-159a18.2; wu:fb99h11; wu:fi35h03; zgc:55444; zgc:77090 | |
Mouse | |
Protein A/G | |
RUO | |
10447 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction